Lessons learned from a clinical trial.
Armstrong
Paul W
PW
University of Alberta, Edmonton, Alberta, Canada. paul.armstrong@ualberta.ca
Newby
L Kristin
LK
Granger
Christopher B
CB
Lee
Kerry L
KL
Simes
R John
RJ
Van de Werf
Frans
F
White
Harvey D
HD
Califf
Robert M
RM
D001241:Aspirin / Q000627:therapeutic use; D035843:Biomedical Research / Q000191:economics / Q000941:ethics / Q000592:standards; D003327:Coronary Disease / Q000401:mortality / Q000517:prevention & control; D004359:Drug Therapy, Combination; D015507:Drugs, Investigational / Q000191:economics / Q000627:therapeutic use; D006805:Human Experimentation / Q000941:ethics / Q000592:standards; D006801:Humans; D033183:Interdisciplinary Communication; D015337:Multicenter Studies as Topic / Q000941:ethics / Q000592:standards; D010091:Oximes / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D011367:Professional Staff Committees; D011787:Quality of Health Care / Q000592:standards; D016032:Randomized Controlled Trials as Topic / Q000191:economics / Q000941:ethics / Q000592:standards*; D055502:Secondary Prevention
D015507:Drugs, Investigational; D010091:Oximes; D010880:Piperidines; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D001241:Aspirin; C100917:sibrafiban